The multimodal artificial intelligence (MMAI) test is the first AI-enabled tool recognized in national guidelines for both predictive and prognostic performance
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced its inclusion in the newly released NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer. The ArteraAI Prostate Test is the only test included for its predictive performance. The test is also the first AI-enabled predictive and prognostic test to be recommended in the guidelines for localized prostate cancer. As one of only four companies referenced within the prostate cancer guidelines, ArteraAI sets itself apart by employing the highest level of evidence and the greatest number of clinical endpoints for its prostate test.
The NCCN Guidelines classify the ArteraAI Prostate Test as having Level IB evidence, according to the Simon Criteria. This designation is based on the rigorous validation of the ArteraAI Prostate Test using multiple randomized, phase 3 clinical trials, showcasing the quality and robustness of the supporting scientific evidence.
“This recognition by the NCCN Guidelines underscores the importance of incorporating innovative tools like the ArteraAI Prostate Test into clinical practice, enabling clinicians and patients to make more informed decisions and personalize treatment strategies,” said Dr. Tim Showalter, Chief Medical Officer of ArteraAI.
“ArteraAI’s inclusion within the guidelines reflects its growing significance in guiding optimal patient care pathways and represents a positive step forward in improving outcomes for individuals battling prostate cancer,” said Dr. Felix Feng, Co-Founder of ArteraAI and Professor of Radiation Oncology, Urology and Medicine at the University of California at San Francisco.
Also Read:InfoMC Drives Innovation to Improve Care Quality, Efficiency & Outcomes
The ArteraAI Prostate Test is included based on a Category 2A recommendation which signifies a uniform NCCN consensus that the tool is appropriate as an option for patients with prostate cancer. Furthermore, the prognostic test has been validated with the most endpoints of any tool for localized prostate cancer, underscoring the test’s potential benefits.
“We are immensely proud of ArteraAI as the inaugural AI company to earn recognition within national guidelines,” said Andre Esteva, CEO and Co-Founder of ArteraAI. “This significant milestone not only celebrates ArteraAI’s success but also paves the way for the integration of AI-enabled solutions into clinical practice, illustrating their potential to enhance personalized patient care.”
The announcement comes off the heels of ArteraAI’s recent achievement of receiving an additional $20 million in funding for continued expansion of the test. The company also announced earlier this year that the Centers for Medicare and Medicaid Services (CMS) decided on the payment rate for the ArteraAI Prostate Test. This decision helps to ensure broader accessibility to AI-enabled personalized care, benefiting a larger population.
The NCCN Guidelines® are widely recognized as the gold standard for clinical practice in oncology and are meticulously updated to reflect the latest advancements and evidence-based practices in cancer care. The guidelines are widely respected and followed by the U.S. physician community and serve to inform and facilitate coverage decisions with payers for oncology therapies. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
SOURCE: BusinessWire
